Palisade Bio, Inc. PALI
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
Palisade Bio, Inc. (PALI) is a healthcare company listed in the US with a market value of about $201M. In the twelve months to September 30, 2026 it had revenue of $500000 and net income of -$44M, a net margin of -8739.2%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is financial health (4/5); the weakest is track record (0/5).
Key numbers: a P/E of 1.2, 5-year revenue growth of -100% a year, a 5-year average ROIC of -158%.
About Palisade Bio
Palisade Bio is listed in the US and classified in biotechnology: biological products (no diagnostic substances). Revenue went from $18833 in 2014 to $250000 in 2023, growth of about 33.3% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 94758% over three years (dilution for shareholders).
Score: 1.4 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $500000 | $0 | $0 | $250000 | $0 | — | $13520 | $15394 | $260000 | $260000 | $16246 |
| Net income | -$44M | -$17M | -$14M | -$12M | -$14M | -$27M | -$10M | -$8M | -$5M | -$16M | -$21M |
| Free cash flow | -$26M | — | -$12M | -$11M | -$13M | -$15M | -$5M | — | -$8M | -$13M | -$16M |
| EPS (diluted) | $0.91 | $-0.30 | $-10.19 | $-27.01 | $-247.95 | $-2546.10 | $-2790.01 | $-2850.01 | $-5655.03 | $-20883.14 | $-44028.61 |
| Net margin | -8739.2% | — | — | -4920.0% | — | — | -76346.1% | -54252.6% | -1894.1% | -6025.4% | -129700.0% |
| ROIC | — | -11.0% | -154.8% | -89.6% | -97.1% | -437.1% | — | — | -107.9% | -123.5% | -108.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $8.70, 677% above the current price; targets range from $5.00 to $16.00; the consensus rating is “Strong buy”; expected EPS is $-0.24 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Palisade Bio’s P/E ratio?
About 1.2, based on the last twelve months of diluted earnings per share.
Does Palisade Bio pay a dividend?
Not currently.
Is Palisade Bio a good stock to buy?
We do not give buy or sell advice. Palisade Bio scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.